 |
This paper is an excellent follow up to the paper by Weggen and colleagues showing that a subset of NSAIDs lower Abeta42 (Nature. 2001 Nov 8;414(6860):212-6.). This current paper provides the in vivo correlate of what Weggen and colleagues observed, and suggests that despite disappointing clinical studies with NSAIDs, particular NSAIDs might be truly beneficial in AD. View all comments by Benjamin Wolozin
|
 |